Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report

被引：0
作者：
Akagi, Yuina [1 ,2 ]
Yamashita, Yusuke [1 ,2 ]
Kosako, Hideki [1 ]
Furuya, Yoshiaki [1 ,2 ]
Hosoi, Hiroki [1 ]
Mushino, Toshiki [1 ]
Murata, Shogo [1 ]
Nishikawa, Akinori [1 ]
Tamura, Shinobu [1 ]
Nakao, Taisei [2 ,3 ]
Sonoki, Takashi [1 ]
机构：
[1] Wakayama Med Univ, Dept Hematol Oncol, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan
[2] Naga Municipal Hosp, Dept Hematol, Wakayama, Japan
[3] Naga Municipal Hosp, Dept Internal Med, Wakayama, Japan
来源：
EJHAEM | 2023年 / 4卷 / 03期
关键词：
acute myeloid leukemia; azacitidine; dialysis; venetoclax; OLDER PATIENTS; PHARMACOKINETICS; 5-AZACYTIDINE; CARE;
D O I：
10.1002/jha2.732
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B-cell lymphoma-2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73-year-old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.
引用
收藏
页码：841 / 843
页数：3
相关论文
共 50 条
  • [11] Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    Chen, Hongli
    Yang, Ruoyu
    Gao, Gongzhizi
    He, Aili
    Wang, Fangxia
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
  • [12] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Zhu, Li-xia
    Chen, Rong-rong
    Wang, Lu-lu
    Sun, Jia-nai
    Zhou, De
    Li, Li
    Qian, Jie-jing
    Zhang, Yi
    Tong, Hong-yan
    Yu, Wen-juan
    Meng, Hai-tao
    Mai, Wen-yuan
    Xie, Wan-zhuo
    Jin, Jie
    Ye, Xiu-jin
    Zhu, Hong-hu
    SUPPORTIVE CARE IN CANCER, 2022, 30 (08) : 7031 - 7038
  • [13] Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience
    Baba, Yuta
    Hida, Noriko
    Sambe, Takehiko
    Abe, Maasa
    Kabasawa, Nobuyuki
    Sakai, Hirotaka
    Yoshimura, Kiyoshi
    Fukuda, Tetsuya
    ANTICANCER RESEARCH, 2024, 44 (05) : 2003 - 2007
  • [14] Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia
    Bouligny, Ian M.
    Murray, Graeme
    Ho, Thuy
    Doyel, Michael
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Alnimer, Yanal
    Zacholski, Kyle
    Venn, Chad
    Wages, Nolan A.
    Grant, Steven
    Maher, Keri R.
    LEUKEMIA RESEARCH, 2023, 134
  • [15] Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia
    Kobayashi, Takahiro
    Sato, Honami
    Miura, Masatomo
    Fukushi, Yayoi
    Kuroki, Wataru
    Ito, Fumiko
    Teshima, Kazuaki
    Watanabe, Atsushi
    Fujishima, Naohito
    Kobayashi, Isuzu
    Kameoka, Yoshihiro
    Takahashi, Naoto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 285 - 296
  • [16] Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia
    Che, Yue
    Tan, Wanqing
    Liu, Ying
    Liu, Haitao
    Li, Lanlan
    Qin, Fangmei
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01) : 209 - 214
  • [17] A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia
    Bazinet, Alexandre
    Kantarjian, Hagop
    Borthakur, Gautam
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias
    Alvarado, Yesid
    Chien, Kelly
    Pemmaraju, Naveen
    Takahashi, Koichi
    Short, Nicholas
    Daver, Naval
    Issa, Ghayas
    Jain, Nitin
    Bull-Linderman, Debra
    DiNardo, Courtney
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Ravandi, Farhad
    Kadia, Tapan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S239 - S240
  • [18] Meta-analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia
    Xie, Yuqin
    Wei, Xueqin
    Wang, Weiwei
    Liao, Changsheng
    Han, Pengfei
    Yu, Yanhui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2024, 27 (04)
  • [19] Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review
    Zhang, Hongyong
    Liu, Jingdi
    Wu, Qiuling
    Xia, Linghui
    ANTI-CANCER DRUGS, 2024, 35 (05) : 440 - 444
  • [20] Case report: Venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome
    Naviglio, Samuele
    Grasso, Antonio Giacomo
    Iacono, Chiara
    Zanella, Giada
    Kiren, Valentina
    Giurici, Nagua
    Verzegnassi, Federico
    Maximova, Natalia
    Rabusin, Marco
    FRONTIERS IN PEDIATRICS, 2023, 10
12345